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Systemic and Mucosal Infection Program Protective Memory
CD8 T Cells in the Vaginal Mucosa1
Pratima Krishna Suvas, Heather M. Dech, Fleurette Sambira, Junwei Zeng, and
Thandi M. Onami2
Whether mucosal immunization is required for optimal protective CD8 T cell memory at mucosal surfaces is controversial. In this
study, using an adoptive transfer system, we compare the efficacy of two routes of acute lymphocytic choriomeningitis viral
infection on the generation, maintenance, and localization of Ag-specific CD8 T cells in tissues, including the vaginal mucosa.
Surprisingly, at day 8, i.p. infection results in higher numbers of Ag-specific CD8 T cells in the vaginal mucosa and iliac lymph
node, as well as 2–3 more Ag-specific CD8 T cells that coexpress both IFN- and TNF- in comparison to the intranasal route
of infection. Expression of the integrin/activation marker CD103 (E7) is low on vaginal mucosal Ag-specific CD8 T cells in
comparison to gut mucosal intraepithelial lymphocytes. At memory, no differences are evident in the number, cytokine production,
or protective function of Ag-specific CD8 T cells in the vaginal mucosa comparing the two routes of infection. However, differences
persist in the cytokine profile of genital tract vs peripheral Ag-specific CD8 T cells. So although the initial route of infection, as
well as tissue microenvironment, appear to influence both the magnitude and quality of the effector CD8 T cell response, both
systemic and mucosal infection are equally effective in the differentiation of protective memory CD8 T cell responses against
vaginal pathogenic challenge. The Journal of Immunology, 2007, 179: 8122–8127.
M any infectious pathogens enter the body via mucosalsurfaces. Consequently, generating and sustaining pro-tective immune responses at mucosal sites is an im-
portant goal in efforts to produce a successful vaccine against viral
infections such as HIV-1, which is primarily transmitted world-
wide through the female genital mucosa (1). Understanding factors
regulating CD8 T cell immunity at sites such as the genital mucosa
will be critical in these efforts.
Discrepancies in the research studies examining cellular immu-
nity in the genital mucosa have led to some confusion regarding
requirements for the generation and maintenance of CD8 T cell
memory in mucosal sites. Several studies established that mucosal
immunization was required for protective mucosal T cell responses
in mice and nonhuman primates (2–5). However, several other
studies have convincingly demonstrated that systemic immuni-
zation with live viral vectors effectively provides protection
against mucosal challenge in nonhuman primates (6, 7). So al-
though recent reviews continue to assert that mucosal immuniza-
tion is required for effective mucosal T cell memory, other studies
have demonstrated long-term T cell memory in the gut mucosa of
mice following mucosal and systemic infection (8–10). Conse-
quently, the importance of mucosal immunization in long-term
cellular immunity in the genital tract should be re-examined.
The male and female genital tracts display several unique features
not shared with other mucosal sites. These include the lack of dis-
tinctive lympho-epithelial structures of the intestinal Peyer’s patches,
and the reduced ability to respond to foreign Ags (11). In this study,
we sought to characterize protective CD8 T cell immune responses in
the vaginal tract of mice following i.p. or intranasal (i.n.)3 infection
with lymphocytic choriomeningitis virus (LCMV) to track and com-
pare the magnitude and quality of Ag-specific CD8 T cell responses.
LCMV is a natural pathogen of mice often spread via inhalation of
aerosolized virus from infected excretions such as fecal matter, urine,
and nasal secretions, in addition to infections by bites (12). Whether
inhaled (i.n.) or given systemically (i.p.), LCMV initiates robust im-
mune responses in mice (13, 14).
Because studying immune responses in the genital mucosa is
technically challenging because of low lymphocyte recovery, we
exploited a model system whereby we adoptively transferred
Thy1.1 transgenic T cells specific for the DbGP33–41 peptide of
the LCMV glycoprotein (15). Our results demonstrate that despite
early differences in the magnitude and quality of the Ag-specific
CD8 T cell response, both routes of infection are able to generate
durable, protective memory CD8 T cells in the vaginal mucosa.
These results suggest that early programming differences in effec-
tor mucosal CD8 T cell responses do not preclude development of
a mucosal memory CD8 T cell population that can mediate pro-
tection to mucosal viral challenge.
Materials and Methods
Mice
C57BL/6 female mice were purchased from The Jackson Laboratory.
Transgenic P14 Thy1.1 female mice were provided by Dr. R. Ahmed
(Emory Vaccine Center, GA) and bred in house. All mice were maintained
under specific pathogen-free conditions at the University of Tennessee in
accordance with university Institutional Animal Care and Use Committee
guidelines and used at 5–8 wk of age.
Department of Microbiology, University of Tennessee, Knoxville, TN 37996
Received for publication August 2, 2007. Accepted for publication October 11, 2007.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by National Institutes of Health Grant AI05771901 and
University of Tennessee start-up funds to T.M.O.
2 Address correspondence and reprint requests to Dr. Thandi M. Onami, Department
of Microbiology, University of Tennessee, Knoxville, TN 37996. E-mail address:
tonami@utk.edu
3 Abbreviations used in this paper: i.n., intranasal; ILN, iliac lymph node; LCMV,
lymphocytic choriomeningitis virus; IEL, intraepithelial lymphocytes; o-NALT, or-
ganized nasal-associated lymphoid tissue.
Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00
The Journal of Immunology
www.jimmunol.org











Adoptive transfer and infections
A total of 106 Thy1.1 P14 transgenic spleen cells were adoptively trans-
ferred into intact C57BL/6 mice followed by infection with 2  105
PFU of LCMV-Armstrong i.p. or i.n. 1 day later. For rechallenge stud-
ies, LCMV-Armstrong immune mice (4 mo postinfection) were proges-
terone synchronized with depo-provera 2 mg/mouse s.c. At day 5 after
progesterone synchronization, mice were rechallenged intravaginally
with 5  107 PFU of Vaccinia virus-expressing GP33– 41 (16).
Tissue harvest and flow cytometry
At specified time points (day 8,  40 postinfection, day 5 postchallenge),
animals were sacrificed and lungs perfused with 5 ml cold PBS before removal
and processing as previously described (9). Serum and vaginal washes were
frozen. The organized nasal-associated lymphoid tissue (o-NALT) and vaginal
tract were removed and pooled from three to four mice. The vaginal tracts
were minced using a tissue chopper and incubated with HBSS plus 1.3 mM
EDTA solution for 30 min at 37°C and then resuspended in 225 U/ml type I
collagenase for 60 min at 37°C. Cell pellets were subjected to a Percoll density
gradient and lymphocytes were collected (yield 1–5  105 cells). Single cell
suspensions were stained with DbGP33–41 tetramer prepared as previously
described (17) and mAbs purchased from BD Pharmingen (Thy1.1, CD8,
CD44, IFN-, and TNF-). Intracellular cytokine staining was assayed on
cells from spleen and iliac lymph node (ILN). All samples were run on a
FACSCalibur (BD Biosciences). All data were analyzed with FlowJo software
(Tree Star). Unpaired Student t tests were performed to determine statistical
significance with  denoting p  0.01, and  denoting p  0.001.
Confocal microscopy and Vaccinia plaque assay
Frozen sections of the vaginal tract (5– 6 m) were fixed and stained
with mAbs Thy1.1, CD8 (BD Pharmingen) as described previously
(18). Confocal microscopy was performed with a laser scanning con-
focal microscope (Leica SP2) and blinded samples were counted to
determine Thy1.1CD8 cells. Plaque assays were performed on ho-
mogenized ovaries using M2-10B4 cells (19).
Results
Ag-specific CD8 T cell responses differ in the genital tract on
day 8 following systemic or mucosal route of LCMV infection
Previous studies have determined that following viral infection, Ag-
specific CD8 T cell responses are robust in many tissues (9, 20). To
determine whether differences exist in the magnitude of the Ag-spe-
cific CD8 T cell response in different tissue compartments depending
on route of infection, we directly compared mice that were adoptively
transferred with transgenic splenocytes specific for the DbGP33–41
peptide of LCMV glycoprotein and were subsequently infected with
2  105 PFU of LCMV Armstrong either via a systemic route (i.p.)
or a mucosal route (i.n.).
Both routes of infection generate robust CD8 T cell responses
in several tissue compartments of individual mice including
spleen, PBMC, lung, bone marrow, cervical lymph node, and
mediastinal lymph node on day 8 (Fig. 1A). Overall, no signif-
icant differences were observed in the total Ag-specific re-
sponses in these tissues comparing i.p. infected vs i.n. infected
mice (Fig. 1, B and C). However, significantly higher numbers
of Ag-specific CD8 T cells are present in the ILN, the draining
node of the genital tract, following i.p. infection compared with
i.n. infection (Fig. 1, D and E). Moreover, whereas the Ag-
specific CD8 T cell responses in the o-NALT at day 8 are sim-
ilar, we show significantly higher numbers of Ag-specific CD8
FIGURE 1. Magnitude of the Ag-specific CD8 T cell response differs in the genital tract on day 8. Lymphocytes from spleen, peripheral blood, lung,
bone marrow, CLN, MedLN, ILN, vaginal tract, and o-NALT were isolated and surface stained with DbGP33–41, CD8. A, Representative FACS staining
of tissues from a day 8 postinfection LCMV Armstrong i.p. or i.n. infected mouse. The numbers represent the percentage of Ag-specific CD8 T cells in
the indicated tissue compartment. B, Total number of Ag-specific CD8 T cells in tissues. C, Percentage of Ag-specific CD8 T cells in PBMC. D,
Representative staining and E, Total numbers of Ag-specific T cells in the ILN. F, Representative staining and G, Total number of Ag-specific CD8
T cells in the vaginal tract and o-NALT. Black/filled symbols are i.p. and white/open symbols are i.n. The data represent three experiments; for
o-NALT and vaginal tract tissues are pooled from four animals, each experiment. Not shown are uninfected control mice that showed no detectable
Ag-specific responses. , p  0.01.
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T cells in the vaginal tract of mice comparing i.p. vs i.n. infec-
tion (Fig. 1, F and G). No differences were noted on the surface
expression of several T cell activation markers between the two
treatment groups (data not shown).
To independently confirm the surprising observations of dif-
ferences in the magnitude of the Ag-specific CD8 T cell
response in the vaginal tract on day 8, we examined micro sec-
tions of the vaginal tract using immunofluorescence staining
and confocal microscopy because FACS analysis of the vaginal
tract requires us to pool tissues from three to four mice per
treatment group to obtain adequate numbers for analysis. Con-
focal analysis allows us to visualize and determine numbers of
Ag-specific CD8 T cells in individual treated mice using costain-
ing of CD8 and Thy1.1 Abs. The vaginal sections of naive animals
show few CD8 T cells and this number increases significantly by
day 8 postinfection (Fig. 2, A–C). However, similar to what we see
by FACS analysis, we show higher numbers of Thy1.1 CD8
Ag-specific cells in the vaginal tract of mice infected with LCMV
via the i.p. route on day 8 compared with mice infected via the
intranasal route (Fig. 2, D–J).
Cytokine production is influenced by route of infection and
tissue localization
Because the magnitude of the Ag-specific CD8 T cell response
differs in the vaginal mucosa on day 8, we also examined the
FIGURE 2. Confocal microscopy confirms differences in the magnitude of the Ag-specific CD8 T cell response in the vagina on day 8. Frozen sections
of the vaginal tract were fixed and stained with CD8 and Thy 1.1 Abs. Thy1.1 staining shows Ag-specific CD8 T cell staining in the stroma of the vaginal
mucosa on day 8 postinfection with LCMV. A, D, and G, CD8 T cells in green and B, E, H, Thy1.1 staining in red. C, F, I, Merged image shows Thy1.1
staining only on CD8 T cells of infected mice. Naive stained only for CD8 T cells. Images were captured using a 20 objective lens. The epithelial layer
is indicated by the white arrowheads (luminal edge) and blue arrowheads (basement membrane). J, Percentage of Ag-specific CD8 T cells in vaginal tract
of infected mice at day 8 postinfection. Thy1.1 CD8 cells were counted on blinded samples. , p  0.001.
FIGURE 3. Cytokine production is influenced by the route of immuni-
zation and tissue localization on day 8. Lymphocytes from spleen and ILN
were isolated on day 8 of i.p. or i.n. LCMV infected mice and after 5 h 
peptide stimulation, stained with Thy1.1, CD8, IFN-, and TNF-. A, Rep-
resentative staining gating on Thy1.1 CD8 Ag-specific cells incubated
with GP33–41 peptide. No staining was seen with no peptide (data not
shown). B, Percentage of IFN- by Ag-specific T cells and C, Percentage
of IFN- TNF- by Ag-specific cells. Data are from three separate
experiments. , p  0.01; , p  0.001.
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quality of these cells by determining cytokine production. Intracellular
cytokine analysis following ex vivo peptide stimulation with
GP33–41 shows that T cells from both i.p. and i.n. infected mice
show similar production of IFN- in spleen and ILN (Fig. 3, A and
B). Notably however, more of the cells coproduce IFN- and
TNF- following the i.p. compared with i.n. route of infection
(Fig. 3, A and C). Moreover, when we compare peripheral vs gen-
ital tract Ag-specific responses in the spleen and ILN respectively,
we observe higher proportions of IFN-TNF- coproducing
cells in the spleen (Fig. 3, A and C). These results suggest that
Ag-specific CD8 T cell responses in the genital tract are different
in the production of inflammatory cytokines compared with pe-
ripheral cells. Higher proportions of these IFN-TNF- Ag-
specific responses are produced in response to systemic infection.
Given these differences in both the magnitude and quality of
Ag-specific responses in the vaginal tract following these different
infection routes at day 8, we asked whether these differences per-
sist at memory. Examination of the vaginal tract by immunofluo-
rescence staining and confocal microscopy show no differences in
the magnitude of the response at memory time points (data not
shown). Examination of spleen, PBMC, lung, bone marrow, cer-
vical lymph node, mediastinal lymph node, ILN, o-NALT, and
vaginal tract reveal no significant differences in the percentages or
total numbers of Ag-specific CD8 T cells following i.p or i.n.
infection at memory (Fig. 6 and data not shown). Furthermore, we
observe no differences in the proportion of Ag-specific memory
CD8 T cells coproducing IFN- and TNF- comparing i.n. vs i.p.
infection (Fig. 4). Importantly however, significant differences per-
sist in cytokine production between the genital tract and peripheral
Ag-specific T cells, with higher proportions of IFN-TNF- in
the spleen vs ILN irrespective of route of infection (Fig. 4, A and
C). Thus, localization of Ag-specific CD8 T cells in the genital
tract appears to influence cytokine production.
Ag-specific CD8 T cells in the genital tract show low levels of
expression of the integrin and activation marker CD103 (E7)
Lymphocytes in mucosal environments have been shown to ex-
press several specific adhesion molecules (21). CD103 is an inte-
grin and activation marker that has been shown to bind E-cadherin,
an integrin receptor shown to have high expression on intestinal
endothelial cells and tonsil (21, 22). CD103 expression has been
shown to be high on Ag-specific memory intestinal intraepithelial
lymphocytes (IELs) and EBV-specific tonsil resident effector-
memory CTLs (21, 23). We determined CD103 expression on Ag-
specific CD8 T cells in the spleen, PBMC, ILN, IEL, and vaginal
tract on day 8 and day 400 of memory (Fig. 5). CD103 expression
is high on Ag-specific gut IELs as has been shown previously, but
remains low on Ag-specific CD8 T cells in the vaginal tract and
ILN at day 8 and memory (Fig. 5) (23). CD103 expression did not
differ on vaginal tract T cells from i.n. vs i.p. infected mice (data
not shown). This result demonstrates that characteristics of Ag-
specific T cells of different mucosal compartments can be unique.
Ag-specific CD8 responses in the vaginal tract of systemic and
mucosal immune mice are protective to mucosal challenge
Although we observe no obvious differences in the magnitude or qual-
ity of memory Ag-specific T cell populations in the i.p. vs i.n. immune
mice, it is possible that subtle differences persist that we have not
identified. To directly compare the protective function of the memory
Ag-specific CD8 T cell population in the absence of potential differ-
ences in the humoral response (data not shown), we challenged mice
with an intravaginal infection of vaccinia expressing the GP33–41
peptide of the LCMV glycoprotein (16). Both groups of immune mice
demonstrate robust amnestic responses at day 5R, with large increases
seen in the vaginal tract and draining ILN (Fig. 6). Intracellular cy-
tokine production at day 5R of Ag-specific CD8 T cells show no
FIGURE 4. Cytokine production of memory T cells is influenced by
tissue localization. Lymphocytes from spleen and ILN were isolated at day
80 and after 5 h  peptide stimulation stained with Thy 1.1, CD8, IFN-,
and TNF-. Gating on Thy 1.1 CD8 cells, stimulation with GP33–41
specific peptide results in IFN- and TNF-. No staining of IFN- or
TNF- was seen with no peptide controls (data not shown). A, Represen-
tative staining showing reduced TNF- coexpressing cells in the ILN com-
pared with spleen. B, Percentage of IFN- and C, Percentage of IFN-
TNF- Ag-specific cells. , p  0.01; , p  0.001.
FIGURE 5. Expression of CD103
on Ag-specific CD8 T cells in genital
mucosa. Lymphocytes were isolated
from the spleen, PBMC, ILN, IEL,
and vaginal tract from day 8 and day
400 LCMV Armstrong i.p. Cells
were stained with CD8, CD103, and
DbGP33–41. Representative staining
is shown, gating on CD8 T cells.
Numbers represent percentage of
CD103high Ag-specific CD8 T cells
in indicated tissue compartments.
For vaginal tract, tissues are pooled
from four to six mice.
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differences in the proportion of IFN-TNF- cells in i.p. vs i.n.
immune mice, although again we note that Ag-specific T cells in the
genital tract show a reduced proportion of these cells compared with
cells in the spleen (Fig. 7, A–C). Importantly, both groups of immune
mice clear virus while naive control mice have detectable virus in the
ovaries at day 5 (Fig. 7D). Similar results were seen at day 3 of
rechallenge (data not shown).
Discussion
In summary, our study demonstrates, using a TCR transgenic transfer
model and LCMV systemic or mucosal route of infection in mice, that
functional, protective CD8 T cell memory is achieved regardless of
the route of infection, despite early differences in the magnitude and
quality of the Ag-specific CD8 effector population in the genital mu-
cosa. Future studies will address whether these early differences in
genital tract CD8 T cell quality and quantity are absent later due to a
redistribution of these cells as they differentiate to memory.
Our study extends recent work demonstrating that activated
CD8 T cells migrate pervasively to nonlymphoid tissues, including
the gut mucosa, regardless of the site of activation using several
viral models (10). Together, these studies demonstrate that irre-
spective of the site of initial Ag encounter, Ag-specific CD8 T cells
widely disseminate to many tissues, including the gut and vaginal
mucosa, and differentiate to functional protective memory T cells
in these sites. Such widespread dissemination likely ensures elim-
ination of the pathogen and provides early sentinels in the event of
secondary infection. Although we cannot solely attribute protec-
tion against reinfection to resident memory T cells in different
tissue compartments, localization of memory T cells at these sites
likely play an important role in early confrontation of pathogens,
significantly compromising the ability of the pathogen to spread.
Earlier studies have suggested that following systemic immuni-
zation, there is a failure to develop protective immune responses at
mucosal sites (2, 3, 5, 24). One significant difference between
those studies suggesting mucosal immunization is required for mu-
cosal protection vs those suggesting systemic immunization can
provide protection is the type of Ag used. In those studies that
demonstrate compartmentalization of the immune response based
on the route of immunization, Ag replication was absent or abor-
tive (2, 3, 5, 24). Our study, in addition to the studies done in
nonhuman primates, used viral systems that initiate via a systemic or
mucosal route, and subsequently disseminate systemically, as is char-
acteristic of HIV infection (6, 7). In many of the live viral vector
studies, functional, protective CD8 T cell memory is achieved in mu-
cosal compartments, regardless of route of immunization (10, 23).
Thus, we suggest that both Ag replication and Ag spread are likely
important determinants in the ability to form functional, protective
memory CD8 responses in mucosal compartments.
Finally, our study also demonstrates that Ag-specific CD8 T cell
responses in the genital mucosa are characterized by a lower propor-
tion of IFN-TNF- cells compared with responses in the spleen.
CD103 expression on Ag-specific CD8 T cells differs between the gut
mucosa and vaginal mucosa, with most Ag-specific CD8 T cells in the
vaginal mucosa having low CD103 expression at day 8 and memory.
Thus, despite the same TCR expression, it appears that localization
within the genital tract influences cytokine expression/activation
FIGURE 6. Intravaginal rechallenge generate protective secondary responses in the genital tract of systemic and mucosal immune mice. Lymphocytes
were isolated from indicated tissues of immune mice and day 5 intravaginal rechallenge with vaccinia expressing the GP33–41 peptide of the LCMV
glycoprotein. A, Representative FACS staining of vaginal tract lymphocytes from i.p. and i.n. day 45 memory and day 5 intravaginal rechallenge mice. B,
Total number of Ag-specific CD8 T cells in indicated tissue compartments of day 80 i.p. or i.n. immune mice and day 5 intravaginal rechallenge mice. Black
bars are i.p. and white bars are i.n. For o-NALT and vaginal tracts, tissues pooled from four animals in each experiment.
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marker profiles of Ag-specific T cells, suggesting that localization
within the genital mucosa leads to a unique differentiation program of
memory T cells. This is supportive of recent work demonstrating dif-
ferences in the quality of Ag-specific responses in the intestinal mu-
cosa and lung airways (9, 25). Future studies will further delineate
characteristics of genital mucosal memory T cells and the possible
role that mucosal dendritic cells may play in modulating unique mem-
ory differentiation programs (26–28).
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FIGURE 7. Cytokine production of secondary effectors following intra-
vaginal rechallenge. A, Representative staining showing IFN-TNF-
coexpressing cells in the ILN vs spleen. B and C, Production of IFN- and
TNF- by Ag-specific CD8 T cells. D, Viral titers in the ovaries on day 5
mice challenged intravaginally with 5  105 PFU vaccinia expressing the
GP33–41 peptide of the LCMV glycoprotein. Gray bar represents naive
mice; black bars are i.p. immune; and white bars are i.n. immune; n 
10–12 mice in each group; , p  0.5; , p  0.001.
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